LSI Medience Corporation today announced that the company has signed an Agreement with Kineticos, a Raleigh-Durham, NC based life sciences consulting company. Kineticos will support LSI Medience in identifying opportunities for Presepsin, a new biomarker in sepsis management, to demonstrate utility in clinical trials.
The Presepsin biomarker testing product has shown potential utility in diagnosis of sepsis, prognosis of septic patients, early risk prediction of mortality in septic patients, assessment of the degree of septic severity and good correlation with clinical score (APACHE II and SOFA).
“Early and accurate diagnosis of sepsis is a critical requirement for improving our ability to identify and treat patients,” according to Kineticos CEO Shailesh Maingi. “We are excited to support LSI Medience in the use of this new biomarker in clinical trials.”
About LSI Medience Corporation
LSI Medience Corporation is a member of the Mitsubishi Chemical Holdings Corporation Group, which is headquartered in Tokyo,Japan. LSI Medience is the first company in Japan to establish a business style that combines clinical and diagnostic laboratory testing services with in vitro diagnostics (IVD) and pharmaceutical development support. One of LSI Medience’s primary business areas is their IVD business, which includes the development, sale, export, and import of in vitro diagnostic reagents and instruments. To learn more, visit the company’s website at http://www.medience.co.jp/english/index.html.
Kineticos Life Sciences is a management consulting practice focused identifying opportunities to drive strategic, sustainable and profitable growth and achieve operational excellence for our clients. Kineticos works with leading pharma, diagnostics, life science tools, CRO, labs and private equity clients to help with their most important challenges. To learn more, visit the company’s website at http://www.kineticos.com.